StockData

BioCryst Pharmaceuticals vs Halozyme Therapeutics

BCRX and HALO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BCRX and HALO compare

Halozyme Therapeutics is the larger company, worth 5.7 times as much as BioCryst Pharmaceuticals ($10.9B against $1.9B).

BioCryst Pharmaceuticals grew revenue faster over the last twelve months (68.7% versus 41.2% for Halozyme Therapeutics).

Halozyme Therapeutics keeps more of each dollar of sales as profit, with a net margin of 24.9% compared with −40.9% at BioCryst Pharmaceuticals.

Halozyme Therapeutics scores higher on the StockData Score (13 against 9 for BioCryst Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBCRXHALO
Size and price
Market cap$1.9B$10.9B
Share price$7.50$95.97
Change, 1 year5.9%37.0%
Change, 5 years−39.9%184%
Beta (5Y)0.580.82
Employees435423
StockData Score
Total score913 (better)
Valuation score1 (better)0
Growth score44
Performance score25 (better)
Health score24 (better)
Dividend score00
Valuation
P/E–28.3×
P/S2.0× (better)6.5×
P/B–75.9×
EV/EBITDA–21.0×
P/FCF5.1× (better)13.5×
PEG–1.34
FCF yield19.5% (better)7.4%
Fair value–$69.98
Margin of safety–−37.1%
Growth
Revenue growth (TTM)68.7% (better)41.2%
Revenue growth, 5Y average118% (better)39.2%
Net income growth (TTM)–−25.8%
EPS growth (TTM)–−22.4%
EPS growth, 5Y average–23.0%
Profitability
Gross margin97.8% (better)82.4%
Operating margin−33.3%35.9% (better)
Net margin−40.9%24.9% (better)
FCF margin39.7%48.5% (better)
Return on equity–174%
Return on invested capital–21.7%
Financial health
Debt / equity–14.95
Net debt / EBITDA–3.24
Interest coverage−4.2×29.4× (better)
Current ratio2.322.71 (better)
Altman Z-score−3.834.45 (better)
Piotroski F-score7 (better)5
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions103%109%
Held by insiders1.9%1.3%
Insider net buying, 12 months−$4.1M (better)−$49.8M
Short interest, % of float11.0%12.2%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.